These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28776577)

  • 1. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.
    Pai RK; Pai RK
    Mod Pathol; 2018 Jan; 31(1):4-23. PubMed ID: 28776577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 3. [The neoadjuvant treatment of gastrointestinal tumors: time for rethinking?].
    Ebert MP; Schmid RM
    Dtsch Med Wochenschr; 2009 Sep; 134(37):1835-7. PubMed ID: 19728255
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
    Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract.
    Matuschek C; Bölke E; Peiper M; Knoefel WT; Budach W; Erhardt A; Scherer A; Gerber PA; Buhren BA; Gattermann N; Baldus SE; Rusnak E; Shukla V; Orth K
    Eur J Med Res; 2011 Jun; 16(6):265-74. PubMed ID: 21810561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
    Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
    Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
    Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
    Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes.
    Zhang ML; Kem M; Rodrigues C; Sandini M; Ciprani D; Hank T; Kunitoki K; Qadan M; Ferrone C; Lillemoe K; Fernández-Del Castillo C; Mino-Kenudson M
    Histopathology; 2020 Jul; 77(1):144-155. PubMed ID: 31965618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
    Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
    AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
    Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
    Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings.
    Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A
    Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
    Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
    Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
    Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
    Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant therapy in pancreatic cancer].
    Ji JF; Li ZY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):644-7. PubMed ID: 16274051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.